1481690-51-0

Basic information

• Product Name: 3-fluorooxan-4-ol
• Synonyms: 3-fluorooxan-4-ol
• CAS NO: 1481690-51-0
• Molecular Formula: C5H9FO2
• Molecular Weight: 120.1221632
• Mol File: 1481690-51-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 203.4±40.0 °C(Predicted)
• Appearance: /
• Density: 1.16±0.1 g/cm3(Predicted)
• PKA: 13.46±0.40(Predicted)
• CAS DataBase Reference: 3-fluorooxan-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-fluorooxan-4-ol(1481690-51-0)
• EPA Substance Registry System: 3-fluorooxan-4-ol(1481690-51-0)

Safety Data

• Hazardous Substances Data: 1481690-51-0(Hazardous Substances Data)

Usage

General Description

3-Fluorooxan-4-ol, also known as 3-fluorooxane-4-ol, is a fluorinated heterocyclic compound with a molecular formula of C4H7FO2. It is a colorless liquid with a slightly sweet odor. This chemical is used as a building block in organic synthesis, particularly in the production of pharmaceuticals and agrochemicals. It is also used as an intermediate in the manufacturing of various materials. 3-Fluorooxan-4-ol is considered to be a potentially hazardous chemical and should be handled with caution, following proper safety protocols and guidelines.

Upstream product

• 17327-22-9 4-methoxy-2,6-dihydropyran 
• 624734-19-6 3-fluorodihydro-2H-pyran-4(3H)-one 
• 1266339-08-5 (R)-3-fluorodihydro-2H-pyran-4(3H)-one 

Downstream Products

• 1422188-17-7 (3R,4S)-3-fluorotetrahydro-2H-pyran-4-amine 
• 1422188-16-6 (3S,4R)-3-fluorotetrahydro-2H-pyran-4-amine 

Relevant articles and documents

Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic

Direct pharmacological inhibition of RAS has remained elusive, and efforts to target CRAF have been challenging due to the complex nature of RAF signaling, downstream of activated RAS, and the poor overall kinase selectivity of putative RAF inhibitors. Herein, we describe 15 (LXH254, Aversa, R.; et al. Int. Patent WO2014151616A1, 2014), a selective B/C RAF inhibitor, which was developed by focusing on drug-like properties and selectivity. Our previous tool compound, 3 (RAF709; Nishiguchi, G. A.; et al. J. Med. Chem. 2017, 60, 4969), was potent, selective, efficacious, and well tolerated in preclinical models, but the high human intrinsic clearance precluded further development and prompted further investigation of close analogues. A structure-based approach led to a pyridine series with an alcohol side chain that could interact with the DFG loop and significantly improved cell potency. Further mitigation of human intrinsic clearance and time-dependent inhibition led to the discovery of 15. Due to its excellent properties, it was progressed through toxicology studies and is being tested in phase 1 clinical trials.

SERINE/THREONINE KINASE INHIBITORS

Compounds having the formula I wherein R2, X and Z as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.

QUINAZOLINE COMPOUNDS AS SERINE/THREONINE KINASE INHIBITORS

Compounds having the formula (I) wherein R1, R2, R3 and Ar as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.